Menu
Search
|

Menu

Close
X

Molecular Templates Inc MTEM.OQ (NASDAQ Stock Exchange Capital Market)

5.00 USD
-0.03 (-0.60%)
As of Jul 20
chart
Previous Close 5.03
Open 5.02
Volume 11,734
3m Avg Volume 26,313
Today’s High 5.04
Today’s Low 4.92
52 Week High 13.25
52 Week Low 4.67
Shares Outstanding (mil) 27.06
Market Capitalization (mil) 136.11
Forward P/E 0.85
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
6
FY16
0
FY15
77
EPS (USD)
FY18
-0.323
FY17
-8.418
FY16
-3.381
FY15
4.972
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
0.85
33.34
Price to Sales (TTM)
vs sector
68.33
8.11
Price to Book (MRQ)
vs sector
1.91
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
5.39
17.18
LT Debt to Equity (MRQ)
vs sector
5.39
13.08
Return on Investment (TTM)
vs sector
-66.04
13.18
Return on Equity (TTM)
vs sector
-72.31
15.09

EXECUTIVE LEADERSHIP

Harold Selick
Chairman of the Board, Since 2017
Salary: $575,000.00
Bonus: --
Eric Poma
Chief Executive Officer, Chief Scientific Officer, Director, Since 2017
Salary: --
Bonus: --
Adam Cutler
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Conrad Jordaan
Senior Vice President - Finance, Corporate Controller, Since 2017
Salary: --
Bonus: --
Nenad Sarapa
Senior Vice President - Clinical Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9301 Amberglen Blvd Ste 100
AUSTIN   TX   78729-1153

Phone: +1512.8961555
Site: mtem.com/

Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

SPONSORED STORIES